

# Application and Contract for Pharmaceutical and Device Pipeline Directory

Directories will be accessible July 2022 through June 30, 2023.

# ASCO®

AMERICAN SOCIETY OF CLINICAL ONCOLOGY  
KNOWLEDGE CONQUERS CANCER

## Step 1: Contact Information

Company Name \_\_\_\_\_

Contact \_\_\_\_\_ Title \_\_\_\_\_

Phone (direct only) \_\_\_\_\_ Mobile \_\_\_\_\_

Email (direct only) \_\_\_\_\_ Website \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_ Country \_\_\_\_\_

I would like to receive communication from ASCO and SPARGO, Inc. regarding opportunities at current and future ASCO meetings. To opt out of receiving these messages at any time, contact [compliance.expo@spargoinc.com](mailto:compliance.expo@spargoinc.com).

## Step 2: Pharmaceutical and Device Pipeline Directory Opportunities

(Phase listing Compound/Device Name must be completed on the following page)

[View Directory Details](#)

Pharmaceutical and Device Pipeline Directory – \$7,500 Per Listing

Total # of Listings: \_\_\_\_\_ Total Discount/Fee\*: \$ \_\_\_\_\_ Total Cost: \$ \_\_\_\_\_

\*Purchase three or more and get a 20% discount on all listings. Non-exhibiting companies may participate for a 20% premium fee above listing price.

The contact person provided above will receive all correspondence pertinent to the Directory, including the confirmation and fulfillment email, and will be responsible for completing and returning items by the stated deadlines. All content is subject to ASCO approval. ASCO reserves the right to make changes to content, as needed. It is the responsibility of the company contact to ensure the company's information is submitted accurately.

## Step 3: Payment and Cancellation

Deposit and Payment Schedule

For Applications Received On or Before September 2, 2022	
By September 2, 2022	50% due
By January 27, 2023	Remaining balance due

For Applications Received Beginning September 3, 2022	
September 3, 2022-January 26, 2023	50% due with application
Beginning January 27, 2023	100% due with application

Cancellation Terms

By September 1, 2022	100% refund
September 2, 2022-January 26, 2023	50% refund
Beginning January 27, 2023	No refund

ASCO requires 50% payment no later than September 2, 2022, and full payment no later than January 27, 2023. Failure to make payments does not release the contracted or financial obligation of Exhibitor. Full refund if cancelled by ASCO without cause.

## Step 4: Acknowledgement

As an authorized representative of the above stated Company, I agree to the payment and cancellation terms included in this agreement. Furthermore, I have received, reviewed, and agree that Company will comply with the Policies for Exhibitors and Other Organizations at ASCO Meetings available on [asco.org/exhibits](http://asco.org/exhibits) (as may be amended from time to time). Company agrees to receive all written and electronic correspondence from ASCO, SPARGO, Inc., and official event contractors related to the Pharmaceutical and Device Pipeline Directory. This application will become a contract upon Company's authorized signature and ASCO's acceptance and approval.

Company Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name \_\_\_\_\_ Telephone \_\_\_\_\_

**ASCO's banking information has changed.** For updated ACH and wire instructions, email [exhibitorservices@spargoinc.com](mailto:exhibitorservices@spargoinc.com).

**Make checks payable to: ASCO**

**Mail check payment to:** ASCO Exposition Management,  
c/o SPARGO, Inc. ♦ 11208 Waples Mill Road, Suite 112 ♦  
Fairfax, VA 22030

**Credit Card Payments:** An invoice will be sent with instructions to submit a credit card payment online. Credit cards will also be accepted by phone at 703-631-6200 or 800-564-4220.

**Submit application to:** [exhibitcontracts@spargoinc.com](mailto:exhibitcontracts@spargoinc.com)

**Need Help? Contact:** [ascoexhibits@spargoinc.com](mailto:ascoexhibits@spargoinc.com)  
703-631-6200 ♦ 800-564-4220

**Step 5: Phase Listing Compound (Drug) / Device Name** (attach additional pages as needed)

Early Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Early Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Early Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Early Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Early Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Early Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Phase 1 Listing – Compound (Drug) / Device Name: \_\_\_\_\_

Phase 2 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Phase 2 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Phase 2 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Phase 2 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Phase 2 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Phase 2 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Beyond Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Beyond Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Beyond Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Beyond Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Beyond Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_

Beyond Phase 3 Listing - Compound (Drug) / Device Name: \_\_\_\_\_